HIGHLIGHTS
- who: Ghislain Opdenakker et al. from the Center, United States University of Calgary, Canada have published the article: How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities?, in the Journal: (JOURNAL)
- future: The authors feel that more and better preclinical research is needed before starting new clinical trials.
SUMMARY
A normal intestinal microbiome is favorable for the host, because e_g it helps with digestion of macromolecules, with biochemical conversions of essential nutrients and even with keeping pathogenic bacteria under control. Activated . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.